Lung

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(AstraZeneca) D9078C00001 / PACIFIC-9A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation TherapyDr Rosalyn JuergensOpen to recruitmentNCT05221840
(CCTG) BR.36A Biomarker-Directed, Open Label, Multi-Centre Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with Non-Small Cell Lung CancerDr Rosalyn JuergensSuspended/On holdNCT04093167
(CCTG) BRC.8/ SWOG S1827/ MAVERICKMRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)Dr Anand SwaminathSuspended/On holdNCT04155034
(HHS) LINNEARRE IPhase I study of neo-adjuvant stereotactic body radiotherapy (SBRT) in operable patients with borderline resectable locally advanced non-small cell lung cancer (NSCLC)Dr Theos TsakiridisOpen to recruitmentNCT02433574
(LHRI) OCELOT / ESR-18-14132OCELOT – Osimertinib then Chemotherapy in EGFR-mutated Lung cancer with Osimertinib Third-line rechallenge Dr Rosalyn JuergensOpen to recruitmentNCT04335292
(Merck) MK-7339-013 / KEYLYNK-013A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Dr Peter EllisOpen to recruitmentNCT04624204
(Merck) MK-7684A-003A Phase 3, Multi-center, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Co-formulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants with PD-L1 Positive (TPS ≥1%) Metastatic Non-Small Cell Lung CancerDr Rosalyn JuergensOpen to recruitmentNCT04738487
(SignalChem) SLC-391-102 / SKYLITEA Single-Arm, Open-Label, Phase 1b/2 Study of SLC-391, an AXL Inhibitor, in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Dr Rosalyn JuergensOpen to recruitmentNCT05860296
Download PDF